[More active therapy in diabetes type 2 is justified by findings in a break-through study. 20-year follow-up of over 5000 patients].
Nilsson
P
P
Kliniska forskningsenheten, Universitetssjukhuset MAS, Malmö.
Attvall
S
S
Eliasson
M
M
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003927:Diet, Diabetic; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D013548:Sweden; D016896:Treatment Outcome; D006113:United Kingdom
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin
Aktivare terapi vid diabetes typ 2 motiveras av fynd i milstolpestudie. 20 års uppföljning av mer än 5,000 patienter.